Home/Pipeline/AP505/B1962

AP505/B1962

Investigational

Phase 2Active

Key Facts

Indication

Investigational

Phase

Phase 2

Status

Active

Company

About AP Biosciences

AP Biosciences leverages a bispecific antibody platform to advance oncology and ophthalmology candidates through late‑stage clinical trials.

View full company profile

Therapeutic Areas

Oncology Ophthalmology

Other Investigational Drugs

Drug	Company	Phase	Status
AP601	AP Biosciences	Phase 1	Active
AP203	AP Biosciences	Phase 1	Active
AP201	AP Biosciences	Phase 1	Active